50 research outputs found
Critical evaluation of latanoprostene bunod in the treatment of glaucoma
No full textGiancarlo A Garcia, Philip Ngai, Sameh Mosaed, Ken Y Lin Department of Ophthalmology, Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA Abstract: Latanoprostene bunod (LBN) is a novel nitric oxide-donating prostaglandin F2α receptor agonist in clinical development for intraocular pressure lowering in open-angle glaucoma and ocular hypertension. Currently in Phase III clinical trials in the USA, European Union, and Japan, LBN has demonstrated promising efficacy while maintaining safety and tolerability. We review preclinical and clinical developmental efforts and evaluate the potential role of LBN monotherapy in the management of open-angle glaucoma and ocular hypertension. The current LBN clinical development program comprises eight trials, four of which have resulted in publication of complete methodology and outcomes. We additionally pool adverse events data to determine incidences across three pivotal studies. Evidence thus far indicates that LBN may be a safe and effective ocular hypotensive agent, although the potential neuroprotective effects and the impact on visual field loss remain to be evaluated. Keywords: uveoscleral outflow, glaucoma medical treatment, ocular hypertension, latanoprostene bunod, nitric oxide, clinical tria
Ab interno trabeculotomy in uveitic glaucoma: Confirmation of original results with extended applications
No full textProstaglandin-Induced Cystoid Macular Edema Following Routine Cataract Extraction
No full textTo our knowledge, we are reporting the first case of a 59-year-old man who developed recurrent CME with three separate trials of three different prostaglandin class drugs following uncomplicated phacoemulsification with intraocular lens implantation. Despite multiple reports of individual prostaglandin (PG) analogues being suggested as the cause of CME, there are no recommendations regarding withholding these medications in the perioperative period. Our
patient first developed CME OD 4-months post uncomplicated cataract extraction. XALATAN (Latanoprost) had been restarted after surgery and discontinued at onset of CME. While off XALATAN (Latanoprost), the patient's CME resolved, but his IOP rose. The patient was started on LUMIGAN (Bimatoprost) to control the IOP, but within weeks his CME recurred. The patient's CME was again treated and his IOP remained acceptable, but then progressively increased. TRAVATAN (Travoprost) was attempted, but he presented with a third round of CME. Definitive conclusions about causal relationships cannot be made without well-designed, prospective clinical trials addressing this issue
Minimally Invasive Glaucoma Surgery and CyPass® Micro-Stent—A New Era in Glaucoma Surgery
No full textIn the largest randomized clinical trial to date on a minimally invasive glaucoma surgery device, the CyPassR Micro-Stent was able to lower intraocular pressure (IOP) more than was modern cataract surgery (phacoemulsification and intraocular lens implantation) alone, and should be considered for patients with mild to moderate glaucoma already scheduled to undergo phacoemulsification surgery. The two-year outcomes of the COMPASS study found mean IOP reductions of 7.4 mmHg in the CyPass Micro-Stent group and no vision-threatening adverse events; more than 98% of subjects in the CyPass Micro-Stent group achieved 20/40 or better best-corrected visual acuity.</jats:p
Ab Externo Imaging of Human Episcleral Vessels Using Fiberoptic Confocal Laser Endomicroscopy.
No full text
